











































Maternal glucocorticoid metabolism across pregnancy: a
potential mechanism underlying fetal glucocorticoid exposure
Citation for published version:
Stoye, DQ, Andrew, R, Grobman, WA, Adam, EK, Wadhwa, PD, Buss, C, Entringer, S, Miller, GE,
Boardman, J, Seckl, J, Keenan-Devlin, LS, Borders, AEB & Reynolds, R 2020, 'Maternal glucocorticoid
metabolism across pregnancy: a potential mechanism underlying fetal glucocorticoid exposure', Journal of
Clinical Endocrinology & Metabolism, vol. 105, no. 3, dgz313. https://doi.org/10.1210/clinem/dgz313
Digital Object Identifier (DOI):
10.1210/clinem/dgz313
Link:




Journal of Clinical Endocrinology & Metabolism
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.





Maternal glucocorticoid metabolism across pregnancy: a potential mechanism underlying fetal 1 
glucocorticoid exposure  2 
 3 
David Q. Stoye1, Ruth Andrew2, William A. Grobman3,4, Emma K. Adam5, Pathik D. Wadhwa6, 4 
Claudia Buss6,7, Sonja Entringer6,7, Gregory E. Miller8, James P. Boardman1, Jonathan R. Seckl2,  5 
Lauren S. Keenan-Devlin9, Ann E.B. Borders4,9, Rebecca M. Reynolds1,2 6 
 7 
Affiliations: 1MRC Centre of Reproductive Health, University of Edinburgh, Edinburgh, UK; 2Centre 8 
for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UK; 3Department of Obstetrics and 9 
Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 4Center for 10 
Healthcare Studies, Institute for Public Health and Medicine, Northwestern University, Chicago, IL, 11 
USA; 5School of Education and Social Policy, Institute for Policy Research, Northwestern University, 12 
Evanston, IL, USA; 6Development, Health and Disease Research Program, University of California, 13 
Irvine, CA, USA; 7Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, 14 
Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Institute of Medical Psychology, 15 
Berlin, Germany; 8Department of Psychology, Institute for Policy Research, Northwestern University, 16 
Evanston, IL, USA; 9Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, 17 
NorthShore University Health System, University of Chicago Pritzker School of Medicine, Chicago, 18 
IL, USA 19 
 20 
Short title: Glucocorticoid metabolism across pregnancy 21 
 22 
Key words: cortisol, glucocorticoid, metabolism, HPA, pregnancy, birthweight 23 
 24 
Corresponding Author: Professor Rebecca M. Reynolds. Centre for Cardiovascular Science, Queen's 25 
Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ. Telephone: + 44 (0) 131 26 
242 6762. Email: r.reynolds@ed.ac.uk. Reprint requests should be made to Professor Rebecca M. 27 






Funding sources: This project was supported by The National Children’s Study, Vanguard Study, Task 30 
Order 5 (HHSN275201200007I-HHSN27500005), and Auxiliary Research Scholar and Research 31 
Career Development Awards from NorthShore University Health System to Ann E.B. Borders. We 32 
acknowledge the support of the British Heart Foundation. David Q. Stoye is supported by a fellowship 33 
from Theirworld. This work was undertaken in the MRC Centre for Reproductive Health at the 34 
University of Edinburgh, which is funded by MRC Centre Grant (MRC G1002033).  We acknowledge 35 
the support of the Wellcome Trust (202794/Z/16/Z). 36 
 37 
Disclosure summary: The authors have no conflicts of interest relevant to this article to disclose. 38 
 39 








Context: Across pregnancy maternal serum cortisol levels rise up to threefold. It is not known whether 44 
maternal peripheral cortisol metabolism and clearance change across pregnancy, or influence fetal 45 
cortisol exposure and development. 46 
 47 
Objectives: The primary study objective was to compare maternal urinary glucocorticoid metabolites, 48 
as markers of cortisol metabolism and clearance, between the 2nd and 3rd trimester of pregnancy. 49 
Secondary objectives were to test associations of total maternal urinary glucocorticoid excretion, with 50 
maternal serum cortisol levels and offspring birthweight z-score. 51 
 52 
Design, participants and setting: 151 women with singleton pregnancies, recruited from prenatal clinic 53 
at the Pittsburgh site of the Measurement of Maternal Stress (MOMS) study, had 24-hour urine 54 
collections during both the 2nd and 3rd trimester. 55 
 56 
Results: Between the 2nd and 3rd trimester total urinary glucocorticoid excretion increased (ratio of 57 
geometric means (RGM) 1.37, 95% CI 1.22-1.52, p<0.001), and there was an increase in calculated 5β-58 
reductase compared to 5α-reductase activity (RGM 3.41, 95% CI 3.04-3.83, p<0.001). During the 3rd 59 
trimester total urinary glucocorticoid excretion and serum cortisol were negatively correlated     (r=-60 
0.179, p=0.029). Mean total urinary glucocorticoid excretion across both trimesters and offspring 61 
birthweight z-score were positively associated (β=0.314, p=0.001). 62 
 63 
Conclusions: The estimated activity of maternal enzymes responsible for cortisol metabolism change 64 
between the 2nd and 3rd trimester of pregnancy. Additionally, maternal peripheral metabolism and 65 






Précis: Maternal urine was sampled as part of a pregnancy cohort. Estimated cortisol metabolism 68 








Glucocorticoids play a critical role in fetal maturation. While a surge in glucocorticoid exposure 73 
towards the end of pregnancy helps prime a fetus for life outside the womb1, excess or inappropriately 74 
timed exposure can adversely programme offspring development2,3. There is growing evidence that 75 
circulating levels of maternal cortisol influence both fetal cortisol exposure and development. Maternal 76 
blood cortisol levels correlate with cortisol levels measured in fetal blood4 and amniotic fluid5. Elevated 77 
cortisol levels measured in maternal blood or saliva are associated with offspring growth restriction and 78 
adverse neurodevelopment and metabolic health6-8. 79 
 80 
Maternal regulation of glucocorticoids changes profoundly across pregnancy, with circulating cortisol 81 
levels rising approximately threefold by delivery9. Multiple factors contribute to maternal 82 
hypercortisolism including rising cortisol binding globulin (CBG)10, placental secretion of corticotropin 83 
releasing hormone (CRH)11, and reduced sensitivity of the hypothalamic-pituitary-adrenal (HPA) axis 84 
to glucocorticoid mediated central negative feedback12. Altered breakdown, clearance and regeneration 85 
of cortisol within maternal peripheral tissues could also influence maternal serum levels and fetal 86 
glucocorticoid exposure.  87 
 88 
Relatively little intact cortisol is excreted from the body passively, with the majority instead being 89 
metabolised to compounds considered more inert before urinary excretion13.  Metabolism of cortisol to 90 
5β-tetrahydrocortisol (THF), and its derivatives α-cortol and β-cortol, and 5α-tetrahydrocortisol (α-91 
THF), are reliant on the activity of A-ring reductases, 5β-reductase, predominantly expressed in the 92 
liver, and 5α-reductase, expressed in both liver and fat. 11β-hydroxysteroid dehydrogenase type 2 (11β-93 
HSD2) acts in the kidney and placenta, converting cortisol to cortisone. In contrast, 11β-hydroxysteroid 94 
dehydrogenase type 1 (11β-HSD1) is most highly expressed in the liver, where it regenerates active 95 
cortisol from inert cortisone. These processes are outlined in figure 1. Peripheral glucocorticoid 96 






The sum of glucocorticoid metabolites measured in a 24-hour sample of urine represents total urinary 99 
glucocorticoid excretion. As the majority of glucocorticoids are excreted in urine this measurement has 100 
also been used as an estimate of glucocorticoid production by the adrenal gland17. Additionally, 101 
comparison of the relative levels of metabolites offers insight into the activity of enzymes converting 102 
cortisol in peripheral tissues. 103 
 104 
To date there has been limited investigation of maternal peripheral glucocorticoid metabolism and 105 
clearance in pregnancy. Longitudinal studies of maternal peripheral glucocorticoid metabolism in 106 
pregnancy have been limited by small sample size18, or have relied on metabolites collected in spot 107 
urine or blood samples that are subject to diurnal variation19,20. There is growing evidence that maternal 108 
peripheral glucocorticoid metabolism and clearance are altered in preeclampsia20-22. There is also 109 
preliminary data supporting a role for peripheral glucocorticoid metabolism influencing fetal 110 
development, with a higher plasma cortisone to cortisol ratio (representing more inert compared to 111 
active glucocorticoid) measured in mothers with psychiatric morbidity during the 3rd trimester, being 112 
associated with higher offspring birthweight23.   113 
 114 
The aims of this study were to assess how maternal urinary glucocorticoid excretion, measured in 24-115 
hour urine, changes between the 2nd and 3rd trimester of pregnancy, and to test the associations of total 116 
urinary glucocorticoid excretion with maternal serum cortisol levels and offspring birth weight z-score. 117 
We tested the hypothesis that total urinary glucocorticoid excretion, as a marker of maternal adrenal 118 
cortisol production, increases across pregnancy, and is negatively associated with offspring birthweight 119 
z-score. 120 
 121 
Materials and Methods 122 
 123 
Participants and clinical protocol 124 
The Measurement of Maternal Stress (MOMS) study was a multisite prospective cohort that recruited 125 





County, PA and San Antonio, TX between June 2013 and May 2014. Exclusion criteria were fetal 127 
congenital abnormality, chromosomal abnormalities, progesterone use before 14 weeks’ gestation, or 128 
regular maternal corticosteroid use. All participating women gave written informed consent, and the 129 
study protocol was approved by the Institutional Review Board of each site. A description of the cohort 130 
has been presented previously24. 131 
 132 
This study reports data from a subset (151 of 200) of mother-baby dyads, recruited from the Pittsburgh 133 
site, who had 24-hour urine collected for measurement of total glucocorticoids and metabolites on two 134 
occasions during pregnancy, between 12.7 and 22.1 weeks’ gestation (2nd trimester), and between 31.9 135 
and 36.4 weeks’ gestation (3rd trimester).  136 
 137 
Participants also had blood collected for measurement of serum cortisol at study visits during the 2nd 138 
and 3rd trimester. Maternal demographic and medical information including body mass index (BMI), 139 
age, ethnicity, diabetes mellitus, preeclampsia, gestational hypertension and offspring outcomes 140 
including birthweight and birth gestation, were recorded either during study visits, or on review of 141 
participants’ medical records. Offspring birthweight z-scores were calculated according to International 142 
Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st) standards25. 143 
 144 
Laboratory methods 145 
 146 
Serum 147 
Serum was obtained by centrifuging whole blood at 1000 g at 4 °C for 15 minutes, then aliquoting 148 
serum into 2mL cryovials. Cortisol was assessed by radioimmunoassay at the Development, Health and 149 
Disease Research Program’s laboratory at the University of California, Irvine.  10% of samples where 150 
measured in duplicate, and inter-assay and intra-assay CVs were <10%. 151 
 152 





Urinary glucocorticoid metabolites were analysed by gas chromatography triple quadrupole mass 154 
spectrometry (GC-MS/MS), at the Edinburgh Clinical Research Facility Mass Spectrometry Core  as 155 
previously described26. The inter- and intra-assay CVs were <13%. Analytes included cortisol (F), 156 
cortisone (E), α-THF, THF, α-cortol, β-cortol, THE, α-cortolone and β-cortolone. The sum of these 157 
measured analytes is referred to as total urinary glucocorticoid excretion. 158 
 159 
The following ratios of urinary metabolites were used as parameters to estimate peripheral 160 
glucocorticoid metabolism: 161 
i) 11β-HSD2 activity = F / E 162 
ii) 11β-HSD total activity = (THF + α-THF) / THE. 163 
iii) Relative 5β-reductase and 5α-reductase activity = THF / α-THF 164 
iv) 5α-reductase activity = F / α-THF 165 
v) 5β-reductase metabolism of F = F / (THF + α-cortol + β-cortol) 166 
vi) 5β-reductase metabolism of E = E / (THE + α-cortolone + β-cortolone) 167 
 168 
Statistical Analysis 169 
All analyses were performed using IBM SPSS Statistics Version 24. Data distributions were assessed 170 
for normality visually using histograms. Serum cortisol levels were normally distributed amongst the 171 
study population. Levels of all excreted urinary glucocorticoid metabolites were positively skewed, and 172 
log base 10 transformed prior to statistical analysis.  173 
 174 
Demographic data is presented as mean ± SD. Change of urinary metabolite excretion between the 2nd 175 
and 3rd trimester was tested using paired t tests, and the degree of change is represented through the 176 
ratio of the geometric means (RGM), with 95% confidence intervals. To assess if peripheral metabolism 177 
has a maintained trait component across pregnancy, the rank stability, i.e. the similarity of where 178 
participants’ estimated enzymatic function fell within the study population’s distribution, at the 2nd 179 
compared to the 3rd trimester, was tested by a linear regression model adjusting for the gestation of urine 180 





levels was tested using Pearson’s Coefficient within both the whole study population and in a subgroup 182 
of patients with blood sampled before 10 am. Finally, the association of maternal total urinary 183 
glucocorticoid excretion and offspring birthweight z-score was tested by linear regression adjusting for 184 
confounding factors. These included the gestation at urine sampling and maternal ethnicity, smoking 185 
status, age, preeclampsia, gestational hypertension, diabetes mellitus (pre-gestational and gestational), 186 
BMI and gravidity. Associations with birthweight z-score were tested for both 2nd and 3rd trimester 187 
glucocorticoid excretion, and for mean glucocorticoid excretion across pregnancy.  A p-value < 0.05 188 





Table 1 shows the characteristics of study participants. Mothers were aged 30.5 ± 5.0 years, with BMI 194 
27.6 ± 7.1 kg/m2, and were predominantly white non-smokers. Mean gestational age at birth was 39.4 195 
± 1.4 weeks, and mean birthweight was 3487 ± 489 grams. 196 
 197 
Changing glucocorticoid levels across pregnancy 198 
Figure 2 and table 2 depict urinary glucocorticoid metabolite excretion for collections during the 2nd 199 
and 3rd trimester. Across pregnancy total urinary glucocorticoid excretion increased (RGM 1.37, 200 
p<0.001).  Excretion of all individual metabolites increased except for α-THF which decreased between 201 
the 2nd and 3rd trimester (RGM 0.55, p<0.001). Assessing individual metabolic pathways, the ratio of F 202 
/ E (RGM 0.90, p<0.001) decreased likely representing increased estimated 11β-HSD2 (inactivation of 203 
cortisol to cortisone) activity across pregnancy. Total body 11β-HSD activity represented by (THF + α-204 
THF) / THE (RGM 1.27, p<0.001) shifted in favour of excretion of cortisol metabolites relative to 205 
cortisone metabolites. The activity of A-ring reductases shifted towards 5β-reductase metabolism 206 
compared to 5α-reductase metabolism with increased THF / α-THF ratio (RGM 3.41, p<0.001).  207 
Between the 2nd and 3rd trimester serum cortisol also increased (ratio of means 1.63, 95% CI 1.40-208 






Individual stability in peripheral glucocorticoid metabolism 211 
Table 3 and figure 3 represent rank-order stability of total urinary glucocorticoid excretion and estimates 212 
of peripheral metabolism of glucocorticoids for participants across the 2nd and 3rd trimester. Despite the 213 
whole group changes in peripheral glucocorticoid metabolism across pregnancy the relative enzymatic 214 
activity of individual participants compared to the whole group was well maintained across both time 215 
points, with women with higher estimated activity for peripheral glucocorticoid metabolism during the 216 
2nd trimester tending to have higher estimated enzyme activity measured in the third trimester.  217 
 218 
Associations between total urinary glucocorticoid excretion and serum cortisol levels 219 
During the 2nd trimester serum cortisol was not associated with total urinary glucocorticoid excretion 220 
(r=0.076, p=0.358). During the 3rd trimester, total urinary glucocorticoid excretion was negatively 221 
associated with serum cortisol within the whole group (r=-0.179, p=0.029). This association between 222 
3rd trimester serum cortisol and total urinary glucocorticoid excretion was largely driven by the 223 
subgroup of participants with  3rd trimester blood samples taken before 10am (n=66, r=-0.354, p=0.004). 224 
In contrast,  for participants with 3rd trimester blood taken after 10am (n=83, r=-0.096, p= 0.390). 225 
 226 
Associations between total urinary glucocorticoid excretion and infant birthweight z-score 227 
In the adjusted models, there were positive associations between total urinary glucocorticoid excretion 228 
during the 2nd trimester and offspring birth weight z-score (β=0.198,  r-square change 0.028, p=0.033), 229 
total urinary glucocorticoid excretion during the 3nd trimester and offspring birth weight z-score 230 
(β=0.202, r-square change 0.032, p=0.023), and mean total glucocorticoid excretion across both 231 
trimesters with offspring birth weight z-score (β=0.314, r-square change 0.066, p=0.001).  In contrast, 232 
there was no association between mean serum cortisol levels and offspring birthweight z-score.  A 233 
visual representation of maternal glucocorticoid excretion across trimesters according to infant 234 






Associations between glucocorticoid metabolite ratios, with serum cortisol and infant birthweight 237 
z-score 238 
Having demonstrated that total urinary glucocorticoid excretion was negatively associated with serum 239 
cortisol during the 3rd trimester and positively associated with birthweight z-score, further exploratory 240 
analysis was undertaken to investigate whether these effects were being driven by the action of 241 
individual metabolic pathways.  In this exploratory analysis, higher 3rd trimester serum cortisol was 242 
associated with estimates of reduced 5α-reductase activity (F / α-THF; whole group r=0.168, p=0.041; 243 
venepuncture <10am subgroup r=0.318, p=0.009), and reduced 5β-reductase activity (F / (THF + α-244 
cortol + β-cortol); whole group r=0.206, p=0.012; venepuncture <10am subgroup r=0.281, p=0.022) 245 
and (E / (THE + α-cortolone + β-cortolone); whole group r=0.252, p=0.002; venepuncture <10am 246 
subgroup r=0.251, p=0.042). No associations were seen between 3rd trimester serum cortisol and 247 
estimated 11β-HSD1 or 11β-HSD2 activity.  Additionally, no association were seen between infant 248 





In this study of pregnant women with detailed measurements of glucocorticoid metabolism we have 254 
demonstrated that glucocorticoid metabolism changes across pregnancy, and that total urinary 255 
glucocorticoid excretion is positively associated with offspring birthweight z-score.   256 
 257 
Within the cohort total maternal glucocorticoid excretion increased between the 2nd and 3rd trimester. 258 
This builds on previous observations of increased urinary free cortisol excretion across pregnancy9, and 259 
likely represents an increase in adrenal cortisol release across pregnancy. There were also differences 260 
in the ratios of urinary metabolites between the 2nd and 3rd trimester. This provides evidence that the 261 
global actions of enzymes working to metabolise cortisol in peripheral tissues changes across 262 
pregnancy. A reduced F/E ratio represents increased 11β-HSD2 activity. An increase in (THF + α-THF) 263 





activity across pregnancy. The ratio of A-ring reductase metabolism shifted profoundly towards 5β-265 
reductase meta27bolism compared to 5α-reductase metabolism with increased THF / α-THF ratio. A 266 
reduction of 5α-reductase cortisol metabolism is in keeping with results from a study where α-THF 267 
excretion measured in maternal urine rose across the first year postpartum28. The action of 5α-reductase 268 
in pregnancy has received attention due to its important role in converting testosterone to 269 
dihydrotestosterone, with 5α-reductase genetic mutation or pharmacological inhibition causing in utero 270 
under-virilization of male offspring29. 5α-reductase metabolism of progesterone has also been 271 
investigated in the context of parturition, with 5α-reductase type 1 deficient mice failing to undergo 272 
cervical ripening at term30. However, to our knowledge the physiological importance of 5α-reductase 273 
metabolism of cortisol in pregnancy has not previously been considered.   274 
 275 
Changes in glucocorticoid metabolism may offer specific advantages to the mother and fetus. In 276 
addition to controlling systemic cortisol inactivation and clearance, peripherally located enzymes play 277 
an important role in regulating glucocorticoid exposure to specific tissues. This is most commonly 278 
discussed in relation to the kidney, where local 11β-HSD2 acts to prevent excessive activation of 279 
mineralocorticoid receptors by cortisol13.  5α-reductase influences cortisol clearance and action within 280 
the liver, and its activity has been shown to be modifiable either by early life stress31, or by variation in 281 
nutritional demands32,33.  Within pregnancy, marked reduction in 5α-reductase activity during the 3rd 282 
trimester may act to enhance cortisol activity in the liver, allowing mobilisation of fuels at a time of 283 
increased metabolic requirements.   284 
 285 
Alternatively, changing glucocorticoid metabolism across pregnancy may be a bystander influenced by 286 
other physiological changes in the mother across pregnancy.  Maternal glucocorticoid metabolism could 287 
be influenced by a changing inflammatory milieu.  For example it has both been demonstrated that 288 
tumor necrosis factor alpha (TNF-α) rises across pregnancy27, and that inhibiting TNFa in patients with 289 
inflammatory arthritis increases 5α-reductase activity34. Changing biliary physiology may also 290 
influence maternal glucocorticoid metabolism, with bile acids holding the potential to inhibit A-ring 291 





glucocorticoid metabolism. However, insulin sensitizing therapies and weight loss have both previously 293 
been associated with decreases in 5α-reductase activity36,37, making it unlikely that changes in insulin 294 
sensitivity are driving the reductions in 5α-reductase activity seen within the 3rd trimester. There is also 295 
likely to be a placental contribution to maternal whole-body glucocorticoid metabolism estimated 296 
through urinary glucocorticoids. In an ex vivo placental perfusion model the majority of cortisone 297 
converted from cortisol at term gestation was transferred back into the maternal circulation rather than 298 
fetal circulation38.  299 
 300 
During the 2nd trimester there was no association between maternal urinary glucocorticoid excretion 301 
and serum cortisol, whilst during the 3rd trimester higher serum cortisol correlated with lower total 302 
urinary glucocorticoid excretion. Additionally, in exploratory analysis, higher serum cortisol in the third 303 
trimester was associated with lower estimated activity of 5β-reductase and 5α-reductase. Individual 304 
differences in peripheral glucocorticoid metabolism and clearance may influence serum cortisol levels 305 
in the later stages of pregnancy. In healthy non-pregnant populations differences in peripheral 306 
glucocorticoid metabolism are generally not associated with serum cortisol levels, likely due to 307 
compensatory glucocorticoid release by the HPA axis in response to changing negative feedback39,40. 308 
However in critically ill patients reduced peripheral metabolism and clearance of cortisol contributes to 309 
raised serum cortisol levels16.  Throughout pregnancy regulation of the maternal HPA axis changes, 310 
becoming progressively less sensitive to negative feedback by glucocorticoids12. It therefore seems 311 
physiologically plausible that by the 3rd trimester individual differences in glucocorticoid metabolism 312 
and clearance influence serum cortisol levels. 313 
 314 
An unexpected finding was the modest positive association between total urinary glucocorticoid 315 
excretion and offspring birthweight z-score, with maternal total urinary glucocorticoid excretion 316 
measured in the 2nd and 3rd trimesters of pregnancy explaining 6.6% of variance in offspring birthweight 317 
z-score. Previous studies have typically reported a negative association between synthetic 318 
glucocorticoid exposure2, or maternal cortisol levels measured in saliva7 or blood41, with infant 319 





measured in the morning between 18-20 weeks’ gestation and fetal growth42. The relationship between 321 
total urinary glucocorticoid excretion and infant birthweight z-score has not previously been tested. 322 
Increased maternal peripheral metabolism and clearance of glucocorticoids may serve as a mechanism 323 
reducing cortisol exposure to the fetus. This theory is strengthened by the negative association found 324 
between serum cortisol and total urinary glucocorticoids observed in the third trimester.  In the 325 
exploratory analyse no associations were found between birthweight z-score and any of the urinary 326 
metabolite ratios used to estimate peripheral enzymatic function, and so it cannot be concluded that this 327 
relationship is driven through the effects of a single enzyme’s function.   Alternatively, the relationship 328 
between maternal total urinary glucocorticoid excretion and infant birthweight z-score could be 329 
mediated by other maternal factors. For example, increased urinary glucocorticoid excretion has 330 
previously been associated with insulin resistance36, and increased maternal insulin resistance during 331 
pregnancy may also act to increase offspring birthweight43.  332 
 333 
Despite whole group changes in peripheral metabolism across pregnancy, individuals’ rank within the 334 
cohort remained relatively stable with those who had higher calculated enzymatic activity during the 335 
2nd trimester also tending to have higher activity during the 3rd trimester.  This implies that individual’s 336 
peripheral metabolism shows a consistent trait across pregnancy, increasing the likelihood that 337 
peripheral glucocorticoid metabolism could influence fetal exposure to cortisol, and play a role in fetal 338 
development. 339 
 340 
Strengths of this study include the use of a modern technique for accurate quantification of urinary 341 
glucocorticoid metabolites26, the large sample size, and longitudinal study design allowing comparison 342 
of urinary metabolites across pregnancy. Limitations include the fact that there was variation in the time 343 
of day blood samples were collected, that participants did not fast before venepuncture, and the lack of 344 
measurement of other serum glucocorticoid metabolites in addition to cortisol.  345 
 346 






Between the 2nd and 3rd trimester the ratios of urinary glucocorticoids, acting as markers of peripheral 349 
metabolism, changed suggesting a relative decrease in 5α-reductase metabolism and relative increase 350 
in 5β-reductase metabolism of cortisol. However inter-individual differences among study participants 351 
were relatively well preserved between the two testing periods. The negative association between total 352 
urinary glucocorticoids and 3rd trimester serum cortisol, along with the positive association between 353 
total urinary glucocorticoids and birthweight z-score, provides preliminary data that peripheral 354 
glucocorticoid metabolism may influence fetal glucocorticoid exposure and fetal growth. 355 
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Figure legends 491 
 492 
Figure 1. Peripheral cortisol metabolism enzymes and metabolites 493 
 494 
Figure 2.  Geometric mean and 95% confidence intervals of glucocorticoid metabolites from 24-hour 495 
urine collections during the 2nd and 3rd trimester.  * p<0.01, ** p<0.001 496 
 497 
Figure 3. Rank correlation across the 2nd and 3rd trimesters of participant total urinary glucocorticoid 498 
excretion or estimated enzymatic function, ** p<001 499 
 500 
Figure 4. Geometric means and 95% confidence intervals of mothers’ mean total urinary 501 
glucocorticoid excretion across trimesters according to offspring birthweight z-score quintile 502 
 503 
Table Legends 504 
Table 1. Maternal, infant and sampling demographics 505 
Table 2. Changes in urinary metabolites excretion and ratios across pregnancy 506 
Table 3. Rank Correlation across the 2nd and 3rd trimesters of participant total urinary glucocorticoid 507 
excretion or estimated enzymatic function 508 





Table 1. Maternal, infant and sampling demographics 510 
Maternal demographics Number (%), Mean 
± SD 
Maternal Age (years) 30.5 ± 5.0 
Maternal BMI (kg/m2) 27.6 ± 7.1 
Gravidity  
-1 50 (33.1%) 
-2 41 (27.2%) 
-≥3 60 (39.7%) 
Ethnicity  
-Hispanic White 1 (0.7%) 
-White 118 (78.1%) 
-Black 27 (17.9%) 
-Other 5 (3.3%) 
Current Smoker  
-Yes 10 (6.6%) 
-No 141 (93.4%) 
Preeclampsia  
-Yes 4 (2.8%) 
-No 139 (97.2%) 
Hypertension  
-Yes 15 (10.5%) 
-No 128 (89.5%) 
Diabetes  
-Yes 9 (6.3%) 
-No 134 (93.7%) 
Infant Demographics  
Infant sex  
-Female 61 (42.7%) 
-Male 82 (57.3%) 
Birthweight (grams) 3487 ± 489 
Birth gestation (weeks) 39.4 ± 1.4 
Birthweight Z-Score 0.56 ± 0.99 
Sampling Demographics  
2nd trimester urine sample gestation 
(weeks) 
17.3 ± 2.4 
3rd trimester urine sample gestation 
(weeks) 
33.9 ±1.2 
2nd trimester blood sample gestation 
(weeks) 
16.7 ± 2.4 
3rd trimester blood sample gestation 
(weeks) 
33.3 ± 1.1 
2nd trimester blood sample time 
(hours after midnight) 
11.0 ± 2.2 
3rd trimester blood sample time 
(hours after midnight ) 
10.6 ±2.5 
 511 
Of the 151 participants included in the study the following data was missing: maternal BMI n = 2, 512 
infant demographics and maternal health during pregnancy n = 8,  2nd trimester serum cortisol n = 1, 513 






Table 2. Changes in urinary metabolites excretion and ratios across pregnancy 516 
 2nd Trimester: Median 
(lower quartile-upper 
quartile) 





RGM (95% CI) 
Urinary metabolites  
(Mg / 24 hours) 
 
THF 1043 (691-1397) 1768 (1066-3269) 1.88 (1.65 to 2.15)2 
α-THF 494 (331-781) 291 (177-436)  0.55 (0.50 to 0.61)2 
THE 2500 (1588-3579) 2799 (1805-4222)  1.13 (1.04 to 1.23)1 
α-cortol 586 (368-917) 641 (455-1140) 1.19 (1.05 to 1.34)1 
β-cortol 545 (259-947) 849 (540-1410) 1.65 (1.45 to 1.88)2 
α-cortolone 2420 (1589-4473) 3685 (2371-6241) 1.46 (1.25 to 1.71)2 
β-cortolone 632 (424-979) 796 (574-1189) 1.29 (1.13 to 1.47)2 
F 231 (160-315) 272 (215-361) 1.23 (1.13 to 1.35)2 
E 228 (171-292) 316 (227-410) 1.36 (1.26 to 1.48)2 
Total urinary glucocorticoids 9691 (6157-12805) 13523 (8955-18269) 1.37 (1.22 to 1.52)2 
Ratios of metabolites   
11β-HSD2 activity 
= F / E 
0.99 (0.78-1.28) 0.88 (0.73-1.16) 0.90 (0.86 to 0.95)2 
11β-HSD total activity 
= (THF + α-THF) / THE 
0.61 (0.52-0.85) 0.76 (0.48-1.23) 1.27 (1.14 to 1.42)2 
Relative 5β -reductase and 5α 
-reductase activity 
 = THF / α-THF 
1.78 (1.33-2.83) 7.19 (3.64-11.74) 3.41 (3.04 to 3.83)2 
5α -reductase activity 
= F / α-THF 
0.45 (0.27-0.60) 0.98 (0.61-1.51) 2.24 (2.00 to 2.50)2 
5β-reductase metabolism of F 
=  F / (THF + α-cortol + β-
cortol) 
0.10 (0.07-0.14) 0.07 (0.05-0.11) 0.72 (0.65 to 0.81)2 
5β-reductase metabolism of E  
= E / (THE + +α-cortolone+ 
β-cortolone) 
0.04 (0.02-0.06) 0.04 (0.03-0.06) 1.05 (0.96 to 1.15) 
 517 









Table 3. Rank Correlation across the 2nd and 3rd trimesters of participant total urinary 523 
glucocorticoid excretion or estimated enzymatic function 524 
 Standardised 
Coefficient, β 
Total urinary glucocorticoids .3872 
11β-HSD2 activity 
= F / E 
.6522 
11β-HSD total activity 
= (THF + α-THF) / THE 
.3522 
Relative 5β -reductase and 5α -reductase 
activity 
 = THF / α-THF 
.5812 
5α -reductase activity 
= F / α-THF 
.4382 
5β-reductase metabolism of F 
=  F / (THF + α-cortol + β-cortol) 
.3282 
5β-reductase metabolism of E  
= E / (THE + +α-cortolone+ β-cortolone) 
.6082 
 525 
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